Oruka Therapeutics Stock Hits Record High on Psoriasis Drug Data, Then Launches $500M Offering

NEW YORK, April 28 —

Oruka Therapeutics (ORKA) surged over 21% to a record high, then immediately filed a $500M stock offering to cash in.

What Actually Happened

Oruka's lead drug, ORKA-001, is a half-life extended IL-23p19 inhibitor designed for once-yearly dosing. That last part is the whole thesis. The IL-23 class already dominates psoriasis treatment. AbbVie's Skyrizi alone did over $10bn in 2025 sales. But existing IL-23 drugs require dosing every 8 to 12 weeks. Once a year would be a genuine step change in patient convenience.

The 64% skin clearance from Phase IIa is the first real clinical signal that extended dosing might work. Analysts responded fast. Guggenheim slapped a $200 price target on a $76 stock. BTIG nearly doubled its target. The market read this as best-in-class potential, and the stock moved accordingly.

Then came the capital raise. Within days of the record high, Oruka filed a $500M underwritten public offering with a $75M greenshoe, potentially raising up to $575M. That is an enormous raise for a company with no revenue and a negative forward P/E of -28.7x. Management saw the window and jumped through it.

The Catch

Phase IIa is early. Critically early. These trials are small and designed to show a signal, not prove efficacy at the level regulators demand. The 64% clearance number will face much tougher scrutiny in Phase IIb/III, where larger patient populations and longer follow-up periods tend to humble early results. Plenty of promising Phase IIa psoriasis drugs have stumbled later.

The $575M raise is also diluting shareholders at what could be the peak of enthusiasm. If you bought ORKA before the data and are sitting on a 21% gain, management just told you they think the stock is expensive enough to sell a lot of it. That is a signal worth weighing against the analyst upgrades.

Bottom Line

The science here is genuinely interesting. Once-yearly dosing in a $30bn+ psoriasis market would be a category-defining product if it holds up. But "if it holds up" is doing a lot of work in that sentence. The stock is priced for a future that is still two or three clinical readouts away, and the company just diluted its shareholders to fund the journey there.

Watch for the Phase IIb/III initiation timeline and durability data from extended follow-up. Those will determine whether ORKA-001 is a real threat to Skyrizi or a nice Phase IIa story that faded.

Want a full financial breakdown on Oruka Therapeutics? Generate a free ORKA report on Basis Report.

Basis Report does not hold positions in securities discussed. This is not investment advice.